794 related articles for article (PubMed ID: 19744292)
1. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
[TBL] [Abstract][Full Text] [Related]
2. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
Berger ML; Mamdani M; Atkins D; Johnson ML
Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
[TBL] [Abstract][Full Text] [Related]
3. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
[TBL] [Abstract][Full Text] [Related]
4. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness research: guidelines for good practices are just the beginning.
Johnson ML; Chitnis AS
Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):51-7. PubMed ID: 21351858
[TBL] [Abstract][Full Text] [Related]
6. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
[TBL] [Abstract][Full Text] [Related]
7. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
[TBL] [Abstract][Full Text] [Related]
8. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
Mullins CD; Sanchez RJ
J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
[TBL] [Abstract][Full Text] [Related]
9. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
[TBL] [Abstract][Full Text] [Related]
10. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
[TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
12. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
13. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
[TBL] [Abstract][Full Text] [Related]
14. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
[TBL] [Abstract][Full Text] [Related]
15. Pre-study feasibility and identifying sensitivity analyses for protocol pre-specification in comparative effectiveness research.
Girman CJ; Faries D; Ryan P; Rotelli M; Belger M; Binkowitz B; O'Neill R;
J Comp Eff Res; 2014 May; 3(3):259-70. PubMed ID: 24969153
[TBL] [Abstract][Full Text] [Related]
16. The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger.
Berger ML
J Comp Eff Res; 2018 Jan; 7(1):11-13. PubMed ID: 29052427
[TBL] [Abstract][Full Text] [Related]
17. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
[TBL] [Abstract][Full Text] [Related]
18. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
Hoaglin DC; Hawkins N; Jansen JP; Scott DA; Itzler R; Cappelleri JC; Boersma C; Thompson D; Larholt KM; Diaz M; Barrett A
Value Health; 2011 Jun; 14(4):429-37. PubMed ID: 21669367
[TBL] [Abstract][Full Text] [Related]
19. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness research in oncology methodology: observational data.
Hershman DL; Wright JD
J Clin Oncol; 2012 Dec; 30(34):4215-22. PubMed ID: 23071228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]